Sorafenib

Where the papers sit

34 papers from the last 6 months study sorafenib directly · updated from PubMed 10 Oct 2026

• Ferroptosis-Based Cancer Therapy

  Cancer ferroptosis research is shifting toward combination treatments and engineered delivery systems that amplify sorafenib-induced cell death. Sorafenib is paired with atorvastatin, decitabine, photodynamic therapy or microRNA delivery to combine ferroptosis with apoptosis or immune activation. Reactive oxygen species and malondialdehyde recur as markers of lipid damage, while SMURF1-EFEMP1, catecholamine signaling and HIF1α-KLF4 help explain resistance. The open challenge is sustaining ferroptosis in resistant tumours without losing treatment selectivity.

  11 papers · 32.4%

• Antiangiogenic Drug Delivery

  Antiangiogenic therapy is moving toward sustained, targeted delivery of sorafenib and biomarker-guided combinations across ocular, renal, prostate and urothelial disease. Intraocular crystals, PSMA-targeted dendrimers and aptamer-functionalized liposomes seek to concentrate exposure while limiting systemic toxicity. VEGFR2, VEGFA, BRAF and related receptor signaling remain recurring targets, with MAPK suppression and endothelial inhibition as key endpoints. Evidence also extends to liver fibrosis, infection and veterinary cancer, so clinical generalization remains open.

  9 papers · 26.5%

• Liver Cancer Therapies

  Liver cancer therapy is moving toward combination strategies that improve sorafenib activity or replace it with immune checkpoint treatment. Lysosomal sequestration, store-operated calcium entry and apoptosis recur as therapeutic targets in hepatocellular carcinoma. Nivolumab plus ipilimumab represents a clinical move toward dual immunotherapy for unresectable disease, while new thiophene-based compounds remain preclinical. Evidence is still fragmented across mechanisms and treatment settings.

  5 papers · 14.7%

• Advanced HCC Treatment

  Advanced hepatocellular carcinoma care is moving beyond sorafenib toward immunotherapy and antiangiogenic combinations, especially atezolizumab plus bevacizumab. Real-world cohorts, economic analyses and treatment-sequencing studies are testing how these regimens perform outside trials and what follows progression. Pretreatment prognostic models aim to select patients for sorafenib, while FTH1P7-driven ferroptosis evasion offers a mechanism for resistance. The key unresolved issue is matching first- and second-line choices to durable survival benefit.

  5 papers · 14.7%

• Cancer Metabolism and Resistance

  Cancer treatment studies here converge on metabolic stress, cell-death regulation and mechanisms of drug resistance. Aurora-A promotes stress-granule assembly through phase separation, whereas pyruvate carboxylase links tumour metabolism to hepatocellular carcinoma growth. Other work tests phase-separating hydrogels and synthetic compounds as ways to improve local therapy or inhibit tumour proliferation. The set suggests mechanistic opportunities but does not establish one dominant therapeutic direction.

  4 papers · 11.8%